Updated May 27, 2007 at 23:46 EST.
Premature ejaculation ( PE )
affects approximately 25-30% of men of all age groups. Currently there are no approved treatments for the condition; Sciele Pharma, Inc. and Plethora Holding Solutions plc would like to change that. A new drug in development for premature ejaculation named PSD502 is touted as a possible treatment for the condition. The new drug combines both prilocaine and lidocaine in a metered spray. The drug has finished its first two clinical trials and will being the third in late 2007.
Patrick Fourteau, Chief Executive Officer of Sciele, stated in a company press release that, “We are enthusiastic about PSD502, which may provide a potential PE treatment, addressing an unmet medical need for millions of men.” Sciele has a $7 million investment in the development and success of PSD502.
Written by the PEhomepage.com Editorial Team.
Back to Articles 
Latest News Archive 
E-mail a Friend
